Investment Summary |
|
|---|---|
| Date | 2017-08-01 |
| Target | PlasmaGen BioSciences |
| Sector | Life Science |
| Investor(s) | Eight Roads |
| Deal Type | Venture |
SEARCH BY
| Category | Private Equity Firm |
|---|---|
| Founded | 1969 |
| PE ASSETS | 11.0B USD |
| Size | Mega |
| Type | Sector Focused |
Eight Roads is a private investment firm focused on a variety of investment opportunities across the US, Europe, and Asia. The Firm is divided into several investment strategies including venture, principal investing, and real estate. Within the principal investments group, Eight Roads backs established growth businesses with long-term capital. Eight Roads does not have any sector preferences, but has experience in fintech, business services, and healthcare. Eight Roads is based in London.
| DEAL STATS | # |
|---|---|
| Overall | 163 of 293 |
| Sector: Life Science M&A | 45 of 73 |
| Type: Venture M&A Deals | 142 of 266 |
| Country: India M&A | 23 of 37 |
| Year: 2017 M&A | 28 of 38 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-07-31 |
WonderPlanet
Nagoya, Japan WonderPlanet designs and develops native language applications and games for smart phones and tablets. It provides 2D and 3D games for iOS and android. WonderPlanet was founded in 2012 and is based in Nagoya , Japan. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-08-10 |
Apellis Pharmaceuticals
Waltham, Massachusetts, United States Apellis Pharmaceuticals is a clinical-stage biopharmaceutical company, focused on the development of a platform of novel therapeutic compounds for the treatment of a broad range of autoimmune diseases based upon complement immunotherapy. Uncontrolled complement activation can lead to a wide range of life-threatening or debilitating disorders. Apellis is the first company to advance chronic therapy with a C3 inhibitor into clinical trials. Apellis Pharmaceuticals was founded in 2009 and is headquartered in Waltham, Massachusetts. |
Buy | - |
